



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁶ : C07D 401/04, C07F 7/08, A61K 31/44, 31/695, C07D 401/14, 451/02, 403/04, A61K 31/445 | A1 | (11) International Publication Number: WO 99/01449 (43) International Publication Date: 14 January 1999 (14.01.99) |
| (21) International Application Number: PCT/EP98/03930 (22) International Filing Date: 26 June 1998 (26.06.98) (30) Priority Data: 9713726.9 30 June 1997 (30.06.97) GB (71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH). (71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1235 Vienna (AT). (72) Inventor; and (75) Inventor/Applicant (for US only): RÉVÉSZ, László [CH/CH]; Ob dem Fichtenrain 7, CH-4106 Therwil (CH). (74) Agent: BECKER, Konrad; Novartis AG, Patent- und Markenabteilung, Lichtstrasse 35, CH-4002 Basel (CH). | | (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |
| (54) Title: 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES <div style="text-align: center;"> <p style="margin-left: 400px;">(I)</p> </div> (57) Abstract <p>Novel 2-substituted 4,5-diaryl imidazoles in which: i) the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent, or ii) the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, amino or hydrazino, or mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members, are provided, in particular compounds of Formula (I) wherein R₁, R₂, R₃ and R₄ are as defined, in free or pharmaceutically-acceptable acid additon salt or physiologically-cleavable ester form, which have p38 MAP kinase (Mitogen Activated Protein Kinase) inhibiting activity. The compounds are used as pharmaceuticals for treating TNFα and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

2-Substituted 4,5-diaryl imidazoles

This invention relates to 2-substituted 4,5-diaryl imidazoles and to their use for treating TNF α and IL-1 mediated diseases such as rheumatoid arthritis and diseases of bone metabolism, e.g. osteoporosis.

Accordingly the present invention provides novel 2-substituted 4,5-diaryl imidazoles in which:

- i) the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent, or
- ii) the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, amino or hydrazino, or mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members, provided that the substituent at the 2 position is not piperidin-4-yl, 1-carboxylic-acid-tert-butyl-ester-4-benzyl-piperidin-4-yl, 1,4-dimethyl-piperidin-4-yl, 4-benzyl-piperidin-4-yl, or piperidin-4-yl which is further substituted only at the N atom

and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

The 4- or 5-aryl substituent may be any of those known in the art; for instance, as described in WO 95/03297 and WO 97/12876. For example, the 4- and 5-aryl substituents may be as hereinafter defined for R₁ and R₂ of formula I and include heteroaryl substituents.

When the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent, the substituent is suitably a trialkylsilylalkoxyalkyl substituent.


When the substituent at the 2 position is arylalkyl, it is conveniently phenylalkyl.

When the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl,

amino or hydrazino, or mono- or bicyclic N-heterocyclyl, it may be further substituted, e.g. by up to 6 substituents selected from halo, OH, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₁₋₄alkoxy, C₁₋₄ thioalkoxy, nitro, amino, C₁₋₄alkylsulphanyl, C₁₋₄ alkylsulphonyl, carboxylate or ester.

Above and elsewhere in the present description the terms halo or halogen denote I, Br, Cl or F, preferably F.

In particular embodiments the invention provides a compound of formula I



wherein

R₁ is 4-pyridyl, pyrimidinyl, quinazolin-4-yl, quinolyl, isoquinolyl, 1-imidazolyl or 1-benzamidazolyl, which is optionally substituted with one or two substituents each of which is independently selected from

C₁₋₄alkyl, halogen, C₁₋₄alkoxy, C₁₋₄alkylthio, NR₅R₆, or an N-heterocyclyl ring having 5 to 7 ring atoms and optionally containing an additional heteroatom selected from O, S, or N

wherein R₅ and R₆ is each independently C₁₋₄alkyl;

R₂ is phenyl, naphth-1-yl or naphth-2-yl which is optionally substituted by up to 5 substituents;

R₃ is hydrogen,

heterocyclyl,

heterocyclylC₁₋₁₀alkyl,

triC₁₋₄alkylsilylC₁₋₁₀alkoxyC₁₋₄alkyl,

optionally halo substituted C₁₋₁₀alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀alkyl, C₃₋₇ cycloalkenyl, aryl, arylC₁₋₁₀alkyl, heteroaryl, or heteroarylC₁₋₁₀alkyl,

optionally mono-or di- C_{1-4} alkyl-substituted C_{0-10} alkyl-oxycarbonyl or -oxythiocarbonyl optionally substituted by C_{1-10} alkyl, C_{3-7} cycloalkyl, heterocyclyl, heterocyclyl C_{1-10} alkyl, aryl, aryl C_{1-10} alkyl, heteroaryl, heteroaryl C_{1-10} alkyl, or

optionally mono-or di- C_{1-4} alkyl-substituted C_{1-10} alkyl

-cyano,

-nitro,

-hydroxy, - C_{1-10} alkoxy, - C_{3-7} cycloalkoxy, -heterocycloxy, -heterocyclyl C_{1-10} alkoxy, -aryloxy, -aryl C_{1-10} alkoxy, -heteroaryloxy, -heteroaryl C_{1-10} alkoxy (and thio oxy analogues thereof),

optionally substituted amino, carboxylate, thiocarboxylate, carbonyl or thiocarbonyl, sulphinyl or sulphonyl;

R_4 is - C_{0-4} alkyl mono-or di- C_{3-7} cycloalkyl optionally substituted by -halo, -OH, - C_{1-4} alkyl, - C_{1-4} alkoxy, - C_{1-4} thioalkoxy, -nitro, -amino, - C_{1-4} alkylsulphinyl, - C_{1-4} alkylsulphonyl, -carboxylate or -ester,

- NR_7R_8 , $NHNHR_9$,

wherein independently each R_7 , R_8 or R_9 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-6} alkynyl,

-X- C_{5-10} aryl (including heteroaryl)

wherein X is S, SO_2 , Se, Te or C_{1-4} alkyl,

mono-or bicyclic N-heterocyclyl in which the N containing ring has six ring members,

or aryl or heteroaryl optionally substituted by up to 4 substituents,

provided that

when R_3 is not tri C_{1-4} alkylsilyl C_{1-10} alkoxy C_{1-4} alkyl,

R_4 is not aryl or heteroaryl optionally substituted by up to 3 substituents, except when R_4 is mono-or bicyclic N-heterocyclyl in which the N containing ring has six ring members, and

provided that

R_4 is not piperidin-4-yl, 1-carboxylic-acid-tert-butyl-ester-4-benzyl-piperidin-4-yl, 1,4-dimethyl-piperidin-4-yl, 4-benzyl-piperidin-4-yl, or piperidin-4-yl which is further substituted only at the N atom,

and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

R_2 is substituted by up to 5 substituents which may be any of the substituents known in the art; for instance, as described for R_4 in WO 95/03297 and the substituent R of WO 97/12876.


When R_4 is $-X-C_{5-10}aryl$, the $C_{5-10}aryl$ or X, when it is $C_{1-4}alkyl$, may be substituted by up to 6 substituents selected from halo, OH, $C_{1-4}alkyl$, $C_{1-4}alkoxy$, $C_{1-4}thioalkoxy$, nitro, amino, $C_{1-4}alkylsulphonyl$, $C_{1-4}alkylsulphonyl$, carboxylate or ester.

When R_4 is mono-or bicyclic N-heterocyclyl in which the N containing ring has six ring members, it may be saturated or unsaturated, e.g. aromatic, heterocyclyl.

When R_4 is aryl or heteroaryl optionally substituted by up to 4 substituents, R_4 may comprise one of the customary aryl or heteroaryl substituents used in the art; for instance as defined for the substituent R_3 of WO 93/03297.

Imidazoles with a 2-substituent, e.g. R_4 as defined above, and with also aryl substituents at both positions 4 and 5, e.g. as defined for R_1 and R_2 above, in which the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent are entirely novel.

Accordingly in a further aspect the invention provides a compound of formula I'



wherein

R_3' is triC₁₋₄alkylsilylC₁₋₁₀alkoxyC₁₋₄alkyl, and R_1 , R_2 and R_4 are as defined above, and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

Compounds of formula I' in which R_4 is H and R_2 , R_3' and R_4 as defined above are key intermediates for the synthesis of other compounds of formula I in which R_3 is not triC₁₋₄alkylsilylC₁₋₁₀alkoxyC₁₋₄alkyl, as hereinafter described.

The substituents R_1 , R_2 , R_3 , R_3' and R_4' independently have the following preferred significances.

Preferably R_1 is 4-pyridyl or pyrimidinyl, especially 4-pyridyl.

R_2 is preferably phenyl, including substituted phenyl.


Most preferably R_3' is trimethylsilylethoxymethyl.

When R_3 is triC₁₋₄alkylsilylC₁₋₁₀alkoxyC₁₋₄alkyl, R_1 is preferably 4-pyridyl.

When R_3 is triC₁₋₄alkylsilylC₁₋₁₀alkoxyC₁₋₄alkyl, R_2 is preferably 4-fluorophenyl.

When R_3 is triC₁₋₄alkylsilylC₁₋₁₀alkoxyC₁₋₄alkyl, R_4 is preferably H.


In a further preferred aspect of the invention R_4 is -X-C₅₋₁₀aryl, preferably -X-phenyl, wherein X is as previously defined, e.g. a compound of formula III



III

wherein R_1 , R_2 , R_3 and X are as defined above and R_{11} represent from 1-4, substituents independently selected from H, halo, OH, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} thioalkoxy, nitro, amino, C_{1-4} alkylsulphinyl, C_{1-4} alkylsulphonyl, carboxylate or ester, and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

In a yet further preferred aspect of the invention R_4 is cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, or mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members, e.g. a compound of formula IV



wherein R_1 , R_2 and R_3 are as defined above, D is C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl or a mono- or bicyclic N-heterocyclyl in which the N containing ring has 6 ring members and X' is a direct bond or $-CR_{12}R_{13}-$

wherein R_{12} is H or C_{1-4} alkyl and R_{13} is H or C_{1-4} alkyl optionally substituted by C_{3-7} cycloalkyl or C_{3-7} cycloalkenyl, and pharmaceutically-acceptable acid addition salts thereof and physiologically-cleavable esters thereof.

In formula IV X' and D may be further substituted, e.g. by up to 6 substituents selected from halo, OH, C_{1-4} alkyl, C_{1-6} alkoxy, C_{1-4} thioalkoxy, nitro, amino, C_{1-4} alkylsulphinyl, C_{1-4} alkylsulphonyl, carboxylate or ester.

Preferably D is cyclohexyl, cyclohexenyl, cyclopropyl, pyridinyl (e.g. 4-pyridinyl), piperidinyl (e.g. piperidin-4-yl), piperidenyl (e.g. piperiden-4-yl), azabicyclo[3,2,1]octanyl, azabicyclo[3,3,1]nonyl or tropanyl bicyclic N-heterocycles (and enyl analogues of such bicyclic N-heterocycles, e.g. 8-azabicyclo[3.2.1]oct-2-en-3-yl). In particularly preferred embodiments $-X'-D$ is 1-hydroxycyclohexyl, 1-aminocyclohexyl, 1-cyclohexenyl, cyclopropylmethyl, 1,2-dicyclopropylethyl, 2,3,5,6-

tetrafluoropyridinyl, 2-amino-3,5,6-trifluoropyridinyl, 2,6-diamino-3,5-difluoropyridinyl, tropan-3-yl, 4-hydroxy-1-methylpiperidinyl, 4-C₁₋₆alkoxy-1-methylpiperidinyl, e.g. 4-n-butyloxy-1-methylpiperidinyl, 8-methyl-8-azabicyclo{3.2.1}oct-2-en-3-yl, 1-methyl-4-piperidinyl.

When R₄ is -X-aryl or -X'-D, R₁ is preferably 4-pyridyl.

When R₄ is -X-aryl or -X'-D, R₂ is preferably halo substituted phenyl, especially 4-fluoro-phenyl.

When R₄ is -X-aryl or -X'-D, R₃ is preferably H.

Particularly preferred compounds of formula IV are those in which X' is a direct bond and D is optionally substituted pyridinyl, e.g. 4-pyridinyl, or piperidinyl, e.g. piperidin-4-yl.


The novel 2-substituted 4,5-diaryl imidazoles of the invention, in particular the compounds of formulae I to IV and the specific compounds of Examples 1-19 are hereinafter referred to as "Compounds of the Invention".

The Compounds of the Invention which comprise free hydroxyl groups may also exist in the form of pharmaceutically acceptable, physiologically cleavable esters, and as such are included within the scope of the invention. Such pharmaceutically acceptable esters are preferably prodrug ester derivatives, such being convertible by solvolysis or cleavage under physiological conditions to the corresponding Compounds of the Invention which comprise free hydroxyl groups. Suitable pharmaceutically acceptable prodrug esters are those derived from a carboxylic acid, a carbonic acid monoester or a carbamic acid, advantageously esters derived from an optionally substituted lower alkanolic acid or an arylcarboxylic acid.

The Compounds of the Invention may also exist in the form of pharmaceutically acceptable salts, and as such are included within the scope of the invention. Pharmaceutically acceptable salts include acid addition salts with

conventional acids, for example, mineral acids, e.g., hydrochloric acid, sulfuric or phosphoric acid, or organic acids, for example, aliphatic or aromatic carboxylic or sulfonic acids, e.g., acetic, propionic, succinic, glycolic, lactic, malic, tartaric, citric, ascorbic, maleic, fumaric, hydroxymaleic, pyruvic, pamoic, methanesulfonic, toluenesulfonic, naphthalenesulfonic, sulfanilic or cyclohexylsulfamic acid; also amino acids, such as arginine and lysine. For compounds of the invention having acidic groups, for example, a free carboxy group, pharmaceutically acceptable salts also represent metal or ammonium salts, such as alkali metal or alkaline earth metal salts, e.g., sodium, potassium, magnesium or calcium salts, as well as ammonium salts, which are formed with ammonia or suitable organic amines.

Compounds of the Invention of formulae III and IV as defined above may be prepared by reacting a compound of formula VIII




wherein R_1 and R_2 are as defined above,

with the corresponding aldehyde, ketone, disulfonylamine, disulfide, diselenide, ditelluride or halide and, if required introducing the desired R_3 substituent or further transforming the product obtained and optionally recovering it free or salt form. Thus for example, the compound of formula VIII is treated with the corresponding aldehyde, ketone, disulfonylamine, disulfide, diselenide, ditelluride or halide in the presence of $n\text{-BuLi}$, e.g. in cooled (e.g. -40°C) THF solution.


When the compound of formula VIII is treated with the corresponding aldehyde or ketone, the initial product obtained is 1-hydroxy substituted in the R_4 substituent, e.g. 1-hydroxycyclohexyl when the ketone is cyclohexanone. The corresponding dehydrated compound, e.g. R_4 is 1-cyclohexenyl, may be obtained, e.g. by treatment with $p\text{TsOH}$ under reflux in toluene solution.

The invention includes a process for the preparation of a Compound of the Invention or salt of formulae III and IV as defined above which comprises reacting a compound of formula VIII



wherein R_1 and R_2 are as defined above,
with the corresponding aldehyde, ketone, disulfonylamine, disulfide, diselenide, ditelluride or halide and, if required introducing the desired R_3 substituent or further transforming the product obtained and optionally recovering the Compound of the Invention in free or salt form.

Compounds of formula VIII may be prepared by treating the corresponding 1H-imidazole of formula I, i.e. the corresponding compound of formula I in which R_4 is H, with 2(trimethylsilyl)ethoxymethyl-halide (e.g. -chloride), e.g. in the presence of potassium bis-(trimethylsilyl)-amide in cooled (e.g. -78°C) DMF/THF solution. This procedure gives rise to a mixture of the corresponding 1-2(trimethylsilyl)-ethoxymethyl-imidazoles of formulae VIII and IX



wherein R_1 and R_2 are as defined above.


Compounds of formula VIII are novel intermediates for preparation of other Compounds of the Invention and are included per se within the present invention. Compounds of formula IX are Compounds of the Invention.

In an alternative preferred embodiment an alkoxyalkyl nitrogen protecting group, e.g. a dialkoxyalkyl nitrogen protecting group, especially a diethoxymethyl protecting group, is used in place of the trimethylsilylethoxymethyl protecting group. Such an alkoxyalkyl protecting group may be introduced by treating the corresponding 1H-imidazole of formula I, i.e. the corresponding compound of formula I in which R₄ is H, with a trialkyl orthoformate, e.g. triethyl orthoformate, for instance as hereinafter described in Example

The synthesis of Compounds of the Invention is further described in the following Examples.

EXAMPLES

Example 1 and 2: 4-(4-fluorophenyl)-5-(4-pyridyl)-1-(2-(trimethylsilyl)-ethoxymethyl)-imidazole and 4-(4-pyridyl)-5-(4-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)imidazole



4-(4-Fluorophenyl)-5-(4-pyridyl)-1H-imidazole (3) (1g 4.18mmol) is dissolved in DMF/THF (50ml/20ml) and cooled to -78 °C. Potassium bis-(trimethylsilyl)-amide (15% in toluene; 6.7ml 5mmol) is introduced at -78 °C, stirred for 30min, then 2-(trimethylsilyl)ethoxymethylchloride is added and the reaction mixture warmed up to r.t. , poured on water after 2 hrs. and extracted 3x with ethyl acetate. The combined organic phases are dried over Na₂SO₄, evaporated to dryness and chromatographed (SiO₂ acetone/hexane 4/6 to 6/4) to give 1-(2-(trimethylsilyl)ethoxymethyl)-4-(4-


fluorophenyl)-5-(4-pyridyl)imidazole, being eluted first as white crystals (218mg 14%) followed by 4-(4-pyridyl)-5-(4-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)imidazole as white crystals (590mg 38%). The correct assignment of the structures was achieved by ROESY, HSQC and HMBC spectrometry.

¹H-NMR (360MHz CDCl₃) of 1-(2-(trimethylsilyl)ethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole (Example 1): 0.00 (s, 9H); 0.92 (t, 2H); 3.55 (t, 2H); 5.15 (s, 2H); 6.95 (t, 2H); 7.36 (d, 2H); 7.42 (dd, 2H); 7.72 (s, 1H); 8.68 (d, 2H)

4-(4-pyridyl)-5-(4-fluorophenyl)-1-(2-(trimethylsilyl)ethoxymethyl)imidazole (Example 2): 0.00 (s, 9H); 0.90 (t, 2H); 3.48 (t, 2H); 5.10 (s, 2H); 7.20 (t, 2H); 7.35-7.45 (m, 4H); 7.75 (s, 1H); 8.45 (d, 2H).


Alternatively, the 1H-imidazole starting material may be converted to the corresponding 4-(4-fluorophenyl)-5-(4-pyridyl)-1-(1,1-diethoxymethyl)-imidazole and 4-(4-pyridyl)-5-(4-fluorophenyl)-1-(1,1-diethoxymethyl)imidazole products.

1-(1,1-Diethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)imidazole and 1-(1,1-diethoxymethyl)-5-(4-fluorophenyl)-4-(4-pyridinyl)imidazole



4-(4-fluorophenyl)-5-(4-pyridinyl)-imidazole (72.7 g; 0.304 mol) and pTsOH.H₂O (1.1 g; 5 mmol) are dissolved in hot triethyl orthoformate (770 ml) and refluxed, while slowly distilling off ca. 300 ml of triethyl orthoformate and ethanol. After 2 h the reaction mixture is evaporated to dryness and taken up in tert.butyl methyl ether (500 ml). Hexane (5 l) is slowly added, the precipitate filtered off and washed with tert.butyl methyl ether/hexane (1:9). The filtrate is washed with 1N Na₂CO₃, dried over Na₂SO₄ and evaporated. Xylene is added twice and evaporated again yielding the title compounds as a yellow-brownish viscous oil (79.3g; 76%; ~1:1 mixture), which is used without further purification.


Example 3: 4-(4-fluorophenyl)-2-((RS)-1-hydroxy-4'-fluorobenzyl)-5-(4-pyridyl)imidazole



1.6M n-BuLi in hexane (0.085ml 0.13mmol) is added at -40 °C to a solution of 1-(2-(trimethylsilyl)ethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole (Example 2; 50mg 0.13mmol) in THF (1.4ml). After 15min at -40 °C, 4-fluorobenzaldehyde (0.018ml 0.18mmol) in THF (0.4ml) is added to the reaction mixture, which is warmed to r.t. and after 10min. poured on water and extracted 3x with ethyl acetate. The combined organic phases are dried over Na₂SO₄, evaporated to dryness and render the desired N-protected title compound (64mg). In order to remove the SEM protecting group, the latter material is dissolved in THF (2ml), treated with Bu₄NF (4.3ml; 1M in THF) for 1h at 60 C, poured on a saturated solution of NaHCO₃ and extracted 3x with ethyl acetate. The combined organic phases are dried over Na₂SO₄, evaporated to dryness and chromatographed (SiO₂ toluene/EtOH/NH₃conc. 90/10/0.6) to yield the title compound as white crystals (32mg 67% over 2 steps)

¹H-NMR (360 MHz DMSO-d₆): 5.80 (s, 1H); 6.30 (bs, OH); 7.15 (t, 2H); 7.20-7.30 (bs, 1H); 7.37 (d, 2H); 7.42-7.48 (m, 2H); 7.52-7.58 (m, 2H); 8.38-8.51 (bs, 2H); 12.50-12.60 (bs, NH)

In an alternative procedure a mixture of 1-(1,1-diethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)imidazole and 3-(1,1-diethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)imidazole, prepared as described above may be used in place of 1-(2-(trimethylsilyl)ethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole; for example as described below for the preparation of 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,3,5,6-tetrafluoropyridinyl)imidazole.

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,3,5,6-tetrafluoropyridinyl)imidazole

1.6 M nBuLi (66 ml; 45 mmol) is added at -45°C to a ~1:1 mixture of 1-(1,1-diethoxymethyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)imidazole and 1-(1,1-diethoxymethyl)-5-(4-fluorophenyl)-4-(4-pyridinyl)imidazole (15 g; 43 mmol) in THF (210 ml). After 15 min. at -45°C the reaction mixture is cooled to -55°C and pentafluoropyridine (5.1 ml; 47 mmol) is rapidly introduced. The cooling bath is removed, the reaction mixture allowed to warm to -15°C and poured on water (1 l), which is then acidified with 2N HCl (100 ml). After stirring for 5 min. the mixture is combined with a saturated solution of Na_2CO_3 and extracted with ethyl acetate three times. The combined organic phases are dried over Na_2SO_4 , filtered and evaporated to dryness rendering the title compound as brownish crystals (16.3 g). Chromatography (SiO_2 ; acetone/hexanes 1:1) yields the title compound together with some unreacted and unprotected imidazole starting material, which could be removed by washing with acetone yielding the title compound (8.7 g; 52.4%).

$^1\text{H-NMR}$ (360 Mhz CDCl_3): 7.30-7.40 (bt, 2H); 7.45 (d, 2H); 7.58 (bq; 2H); 8.52 (bs, 2H).

MS (m/z): 388.9 (MH $^{+}$)

Using substantially similar procedures to those described in Example 3 and appropriate starting materials the following compounds of formula X are prepared as set out in Table I.














Table 1

| Example No. | X'' | D' | NMR data etc. |
|-------------|--------------------|---|--|
| 4 | -SO ₂ - |  | ¹ H-NMR (360 MHz DMSO-d ₆): 7.28 (t, 2H); 7.35 (d, 2H); 7.49 (m, 2H); 7.67-7.80 (m, 3H); 8.05 (d, 2H); 8.50 (d, 2H) |
| 5 | -S- |  | ¹ H-NMR (360 MHz DMSO-d ₆): 7.20-7.45 (m, 9H); 7.55 (dd, 2H); 8.40-8.60 (m, 2H) |
| 6 | -Se- |  | ¹ H-NMR (360 MHz DMSO-d ₆): 7.25-7.36 (5H); 7.40 (d, 2H); 7.48-7.55 (m, 4H); 8.48 (d, 2H) |
| 7 | direct bond |  | ¹ H-NMR (360 MHz DMSO-d ₆), 7/3 mixture of NH-tautomers: 1.20-1.40 (bs, 1H); 1.51 (bs, 3H); 1.60-1.72 (m, 2H); 1.72-1.85 (m, 2H); 1.90-2.05 (M, 2H); 5.60 (s, 0.7H); 5.67 (s, 0.3H); 7.12-7.21 (bt, 0.3H); 7.30 (bt, 0.7H); 7.40 (d, 2H); 7.48 (bt, 2H); 8.40 (bd, 1.4H); 8.48 (bd, 0.6H); 12.26 (s, 1H) |
| 8 | direct bond |  | ¹ H-NMR (360 Mhz DMSO-d ₆): 0.00 (bs, 1H); 0.20-0.30 (m, 2H); 0.32-0.43 (m, 2H); 0.50-0.60 (m, 1H); 0.65-0.75 (m, 1H); 1.05-1.15 (m, 1H); 1.60-1.70 (m, 1H); 1.81-1.91 (m, 1H); 2.10-2.20 (m, 1H); 7.15-7.40 (m, 4H); 7.50 (dd, 2H); 8.40 (bs, 1H); 8.45 (bs, 1H); 12.20 (bs, 1H) MS (m/z): 348 (MH ⁺) |
| 9 | -CH ₂ - |  | ¹ H-NMR (360 Mhz CDCl ₃): 0.48 (q, 2H); 0.68 (q, 2H); 1.20 (m, 1H); 2.84 (d, 2H); 7.10 (t, 2H); 7.45 (dd, 2H); 7.55 (d, 2H); 8.45 (d, 2H) MS(m/z):294(MH ⁺) |

| Example No. | X'' | D' | NMR data etc. |
|-------------|-------------|--|--|
| 10 | direct bond |  | ¹ H-NMR (360 Mhz CDCl ₃): 7.30-7.40 (bt, 2H); 7.45 (d, 2H); 7.58 (bq; 2H); 8.52 (bs, 2H). MS (m/z): 388.9 (MH ⁺) |
| 11 | direct bond |  | ¹ H-NMR (360 Mhz DMSO): 1.83 (bd, 2H); 1.90 (bs, 2H); 2.13 (bd, 2H); 2.25 (bs, 2H); 2.40 (bd, 2H); 3.12 (bs, 3H); 5.15 (bs, 1H); 7.20-7.30 (bs, 2H); 7.46 (d, 2H); 7.45 (dd, 2H); 8.35-8.50 (s, 2H); 12.25 (s, 1H). MS (m/z): 377.1 (MH ⁻) |
| 12 | direct bond |  | ¹ H-NMR (360 Mhz DMSO, 120 C): 2.18 (bt, 1H); 2.21 (bt, 1H); 2.40-2.50 (m, 2H); 2.78 (s, 3H); 2.7-2.95 (bm, 4H); 5.45 (bs, 1H); 7.21 (dd, 2H); 7.42 (dd, 2H); 7.51 (dd, 2H); 8.45 (dd, 2H). MS (m/z): 352 (M ⁺) |

Example 13: 2-(1-Cyclohexenyl)-4-(4-fluorophenyl)- 5-(4-pyridyl)imidazole



The product of Example 7, 2-((1-hydroxy)cyclohexyl)-4-(4-fluorophenyl)- 5-(4-pyridyl)-1H-imidazole (50mg 0.15mmol) is dissolved in toluene (100ml) and refluxed with pTsOH (100mg) for 15min. The reaction mixture is poured on saturated NaHCO₃ and extracted 3x with ethyl acetate. The combined organic phases are dried over

Na₂SO₄, evaporated to dryness and chromatographed (SiO₂ acetone/hexane 4/6) to render the title compound as white crystals (38mg 81%)

¹H-NMR (360 MHz DMSO-d₆), 8/2 mixture of NH-tautomers: 1.60 (m, 2H); 1.68 (m, 2H); 2.18 (bs, 2H); 2.50 (bs, 2H); 6.55 (bs, 0.8H); 6.62 (bs, 0.2H); 7.15-7.60 (m, 6H); 8.40 (d, 1.6H); 8.52 (d, 0.4H); 12.25 (bs, 0.2H); 12.37 (bs, 0.8H)

Using substantially similar procedures to those described in Example 13 and appropriate starting materials the following compounds of formula X are prepared as set out in Table 2





Table 2

| Example No. | X'' | D' | NMR data etc. |
|-----------------|-------------|----|---|
| 14 | direct bond | | ¹ H-NMR (360 Mhz DMSO, 120 C): 1.55-1.65 (m, 2H); 1.72 (dt, 2H); 2.00-2.18 (m, 2H); 2.22 (d, 1H); 2.35 (s, 3H); 3.35 (bt, 1H); 3.42 (bt, 1H); 6.68 (bs, 1H); 7.10-7.30 (bd, 2H); 7.40 (d, 2H); 7.50 (dd, 2H); 8.35-8.55 (bd, 2H); 12.00 (bs, 1H). MS (m/z): 361.1 (M+H+). |
| 15 ₁ | direct bond | | ¹ H-NMR (360 MHz, DMSO, 120 C): 2.35 (s, 3H); 2.65 (s, 4H); 3.10 (s, 2H); 6.55 (bs, 1H); 7.10-7.30 (bd, 2H); 7.42 (bs, 2H); 7.52 (bt, 2H); 8.35-8.55 (bd, 2H); 11.90-12.10 (bs, 1H). MS (m/z): 334 (M+). |

1 - SOCl₂ in pyridine is used in place of pTsOH in toluene

Example 16 and 17: 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2-amino-3,5,6-trifluoropyridinyl)imidazole and 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,6-diamino-3,5-difluoropyridinyl)imidazole



The product of Example 10, 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,3,5,6-tetrafluoropyridinyl)imidazole (2g; 5.15mmol) is suspended in NH_3 conc. (25%; 200ml) and heated to 150°C in a sealed steel cylinder for 5h. Water is evaporated and the residue chromatographed (SiO_2 , TBME/MeOH/ NH_3 conc 98/2/0.2) to yield the title compounds 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2-amino-3,5,6-trifluoropyridinyl)imidazole (880mg; 44.4%) and 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,6-diamino-3,5-difluoropyridinyl)imidazole (650mg; 33%) as slightly colored crystals.

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2-amino-3,5,6-trifluoropyridinyl)imidazole

$^1\text{H-NMR}$ (400MHz, DMSO-d_6) mixture of tautomers: 6.80 (s, 2H); 7.25 (bt, 0.6H); 7.38 (t, 1.4H); 7.45 (d, 2H); 7.58 (t, 2H); 8.49 (d, 1.4H); 8.62 (bd, 0.6H)

MS (m/z): 385 (M+)


4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,6-diamino-3,5-difluoropyridinyl)imidazole:

$^1\text{H-NMR}$ (400MHz, DMSO-d_6) mixture of tautomers: 5.75 (s, 2H); 7.22 (t, 0.6H); 7.33 (t, 1.4H); 7.41-7.47 (m, 2H); 7.52-7.58 (m, 2H); 8.47 (d, 1.4H); 8.58 (d, 0.6H)

MS (m/z): 382 (M+)


Example 18: 4-(4-Fluorophenyl)-2-((1-amino)cyclohexyl)-5-(4-pyridyl)imidazole

a) 1-(4-Fluorophenyl)-2-bromo-2-(4-pyridyl)ethanone hydrobromide



Bromine (74.4g; 0.46mol) in acetic acid (160ml) is added within 10min to a solution of 4-fluorophenyl 4-pyridylmethylketone (I.Lantos et al. J.Med.Chem. 1984, 27, 72-75) (100g; 0.46mol) in acetic acid (800ml) at 21°C. The yellow crystals are filtered off, washed with acetic acid, ether and hexane and then dried under reduced pressure to provide the hydrobromide of the desired compound (250g; 72%).

b) 4-(4-Fluorophenyl)-2-(1-N-carbobenzyloxycyclohexyl)-5-(4-pyridyl)imidazole




1-N-carbobenzyloxy-1-cyclohexanecarboxylic acid (E.Didier et al. Tetrahedron 1992, 48(39), 8471) (13.9g; 50mmol), and ammoniumcarbonate (Fluka; 4.8g; 50mmol) are dissolved in DMF (50ml) and heated to 110°C for 10min. until gas evolution ceases. The reaction flask is cooled to 60°C, 1-(4-fluorophenyl)-2-bromo-2-(4-pyridyl)ethanone hydrobromide (3.75g; 10mmol) added as a solid and heated to 125°C for 2.5h. The reaction mixture is poured on 1M Na₂CO₃ and extracted with ethyl acetate three times. The combined organic phases are washed with water, dried over Na₂SO₄, evaporated to dryness and yielded the crude title compound, (4.8g) which after chromatography (SiO₂; ethyl acetate) gives the pure title compound as light yellow crystals (1.4g; 30%).

¹H-NMR (400MHz; CDCl₃): 1.25-2.40 (m, 10H); 5.12 (s, 2H); 7.08-7.16 (m, 2H); 7.30-7.50 (m, 9H); 8.50 (d, 2H)

MS (m/z): 471.2 (MH⁺)

c) 4-(4-Fluorophenyl)-2-(1-aminocyclohexyl)-5-(4-pyridyl)imidazole (243-653)




4-(4-Fluorophenyl)-2-((1-N-carbobenzyloxy)cyclohexyl)-5-(4-pyridyl)imidazole (1.6g; 4mmol) is dissolved in EtOH (140ml) and hydrogenated at 1 atm in the presence of Pd/C (10%; 0.7g) for 2h at room temperature. Filtration and evaporation of the solvent followed by recrystallisation from ethyl acetate/ether yields the desired amine as off-white crystals (0.63g; 47%).

¹H-NMR (400MHz; DMSO-d₆): 1.25-1.78 (m, 8H); 1.95-2.10 (bt, 2H); 7.25-7.34 (bt, 2H); 7.40 (d, 2H); 7.47-7.52 (m, 2H); 8.43 (d, 2H)

MS (m/z): 336 (M⁺)

Example 19: 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(4-n-butyloxy-1-methylpiperidin-4-yl)imidazole



The product of xample 12, 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(4-hydroxy-1-methylpiperidin-4-yl)imidazole (22.2g; 63 mmol) is dissolved in 1-butanol (1 l) upon warming to 40° C. H₂SO₄ conc (27.8g; 283 mmol) is added dropwise and the initially resulting suspension is refluxed for 3.5 h, while distilling off ~200ml of 1-butanol. The reaction mixture is cooled to room temperature and poured on a saturated solution of

Na₂CO₃ (500 ml). The aqueous phase is extracted with ethyl acetate and the combined organic phases dried over Na₂SO₄, filtered and evaporated to dryness. Purification by chromatography (SiO₂; TBME/MeOH/NH₃conc. 96/4/0.4 to 70/30/1) yields the title compound as yellow crystals (15.5g; 60.3%). A sample is recrystallized from CH₂Cl₂/TBME to render colorless crystals: m.p. 177° C.

¹H-NMR (400MHz; DMSO-d₆): mixture of tautomers, which duplicates aromatic signals. 0.80 (bt, 3H); 1.25-1.35 (m, 2H); 1.38-1.48 (m, 2H); 2.12 (bs, 4H); 2.18 (s, 3H); 2.35 (m, 2H); 2.42 (m, 2H); 3.12 (t, 2H); 7.18 (t, 0.5H); 7.32 (t, 1.5H); 7.40 (m, 2H); 7.48 (m, 2H); 8.40 (d, 1.5H); 8.53 (d, 0.5H).

MS (m/z): 408 (M⁺, 20%); 351 (100%); 335 (95%).

Compounds of the Invention, in free or pharmaceutically acceptable acid addition salt or physiologically cleavable ester form, which exhibit pharmacological activity and are useful as pharmaceuticals, e.g. for therapy, in the treatment of diseases and conditions as hereinafter set forth, are hereinafter referred to as Agents of the Invention.

In particular Agents of the Invention possess p38 MAP kinase (Mitogen Activated Protein Kinase) inhibiting activity. Thus the Agents of the Invention act to inhibit production of inflammatory cytokines, such as TNF- α and IL-1, and also to potentially block the effects of these cytokines on their target cells. These and other pharmacological activities of the Agents of the Invention as may be demonstrated in standard test methods for example as described below:

p38 MAP kinase Assay

The substrate (GST-ATF-2; a fusion protein comprising amino acids 1-109 of ATF-2 and the GST protein obtained by expression in *E. coli*) is coated onto the wells of microtiter plates (50 μ l/well; 1 μ g/ml in PBS/0.02% Na azide) overnight at 4 °C. The following day, the microtiter plates are washed four times with PBS/0.5% Tween 20/0.02% Na azide and are blocked with PBS/2% BSA/0.02% Na Azide for 1 h at 37 °C. Plates are washed again 4 times with PBS/0.5% Tween 20/0.02% Na azide. The

kinase cascade reaction is then started by adding the following reactants in 10 μ l aliquots to a final reaction volume of 50 μ l.

1. Agents of the Invention titrated from 10 to 0.001 μ M in 10-fold dilutions or solvent (DMSO) or H₂O.
2. Kinase buffer (5x); pH 7.4; 125 mM Hepes (Stock at 1M; Gibco #15630-056), 125 mM β -glycerophosphate (Sigma #G-6251):125 mM MgCl₂ (Merck #5833); 0.5 mM Sodium orthovanadate (Sigma #5-6508), 10 mM DTT (Boehringer Mannheim #708992). The (5x) kinase buffer must be prepared fresh the day of the assay from 5x stock solutions kept at RT. DTT is kept at -20 °C and is added as the last reagent.
3. His-p38 MAP kinase (10 ng/well; Novartis - a fusion protein comprising full length murine p38 MAP kinase and a His tag, obtained by expression in E. coli)
4. cold ATP (final concentration 120 μ M; Sigma #A-9187)
5. Water

After 1h at 37 °C the kinase reaction is terminated by washing the plates four times as previously described. Phosphorylated GST-ATF-2 is then detected by adding:

1. the PhosphoPlus ATF-2 (Thr71) Antibody (50 μ l/well; 1/1000 final dilution in PBS/2% BSA/0.02% Na Azide; New England Biolabs #9221L) for 90 min at RT.
2. Biotin labelled goat-anti-rabbit IgG (50 μ l/well; 1/3000 final dilution in PBS/2% BSA/0.02% Na Azide; Sigma #B-9642) for 90 min at RT.
3. Streptavidin-alkaline phosphatase (50 μ l/well; 1/5000 dilution in PBS/2% BSA/0.02% Na Azide; Jackson ImmunoResearch #016-050-084) for 30 min at RT.
4. Substrate (100 μ l/well; Sigma 104 Phosphatase substrate tablets, 5 mg/tablet; #104-105; 1 mg/ml in substrate buffer, Diethanolamine (97 ml/l; Merck #803116) + MgCl₂.6H₂O (100 mg/l; Merck #5833) + Na Azide (0.2 g/l) + HCl 1M to pH 9.8) 30 min at RT.

After step 1,2 and 3 the microtiter plates are washed four times with PBS/0.5% Tween 20/0.02% Na azide. After step 4, the plates are read in a Bio-Rad microplate reader in a dual wavelength mode (measurement filter 405 nm and reference filter 490 nm). The background value (without ATP) is subtracted and IC₅₀ values are calculated using the Origin computer program (4 parameter logistic function).

Agents of the Invention typically have IC_{50} s for p38 MAP kinase inhibition in the range from about 1 μ M to about 10 nM or less when tested in the above assay. For example, the compound of Example 17 has an IC_{50} of about 10 nM in this assay.

Assay for Inhibition of TNF- α release from hPBMCs

Human peripheral blood mononuclear cells (hPBMCs) are prepared from the peripheral blood of healthy volunteers using ficoll-hypaque density separation according to the method of Hansell et al., J. Imm. Methods (1991) 145: 105. and used at a concentration of 10^5 cells/well in RPMI 1640 plus 10% FCS. Cells are incubated with serial dilutions of the test compounds for 30 minutes at 37°C prior to the addition of IFNg (100 U/ml) and LPS (5 mg/ ml) and subsequently further incubated for three hours. Incubation is terminated by centrifugation at 1400 RPM for 10 min. TNF- α in the supernatant is measured using a commercial ELISA (Innotest hTNFa, available from Innogenetics N.V., Zwijnaarde, Belgium). Agents of the Invention are tested at concentrations of from 0 to 10 mM. Exemplified Agents of the Invention typically suppress TNF release in this assay with an IC_{50} of from about 1 μ M to about 10 nM or less when tested in this assay. For example, the compound of Example 17 has an IC_{50} of about 90 nM when tested in this assay.

Assay for Inhibition of TNF- α Production in LPS stimulated mice

Injection of lipopolysaccharide (LPS) induces a rapid release of soluble tumour necrosis factor (TNF- α) into the periphery. This model is be used to analyse prospective blockers of TNF release in vivo.

LPS (20 mg/kg) is injected i.v. into OF1 mice (female, 8 week old). One (1) hour later blood is withdrawn from the animals and TNF levels are analysed in the plasma by an ELISA method using an antibody to TNF- α . Using 20 mg/kg of LPS levels of up to 15 ng of TNF- α / ml plasma are usually induced. Compounds to be evaluated are given either orally or s.c. 1 to 4 hours prior to the LPS injection. Inhibition of LPS-induced TNF-release is taken as the readout.

Agents of the Invention typically inhibit TNF production to the extent of from about 50% up to about 90% or more in the above assay when administered at 10 mg/kg p.o.. For example the compound of Example 17 inhibits TNF production to the extent of about 80% in this assay.

As indicated in the above assays Agents of the Invention are potent inhibitors of TNF- α release. Accordingly, the Novel Compounds have pharmaceutical utility as follows:

Agents of the Invention are useful for the prophylaxis and treatment of diseases or pathological conditions mediated by cytokines such as TNF α and IL-1, e.g., inflammatory conditions, autoimmune diseases, severe infections, and organ or tissue transplant rejection, e.g. for the treatment of recipients of heart, lung, combined heart-lung, liver, kidney, pancreatic, skin or corneal transplants and for the prevention of graft-versus-host disease, such as following bone marrow transplants.

Agents of the Invention are particularly useful for the treatment, prevention, or amelioration of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an aetiology including an autoimmune component such as arthritis (for example rheumatoid arthritis, arthritis chronica progrediente and arthritis deformans) and rheumatic diseases. Specific auto-immune diseases for which Agents of the Invention may be employed include autoimmune haematological disorders (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, scleroderma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including e.g. ulcerative colitis and Crohn's disease), endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary biliary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis and glomerulonephritis (with and without nephrotic

syndrome, e.g. including idiopathic nephrotic syndrome or minimal change nephropathy).

Agents of the Invention are also useful for the treatment, prevention, or amelioration of asthma, bronchitis, pneumoconiosis, pulmonary emphysema, and other obstructive or inflammatory diseases of the airways.

Agents of the Invention are useful for treating undesirable acute and hyperacute inflammatory reactions which are mediated by TNF, especially by TNF α , e.g., acute infections, for example septic shock (e.g., endotoxic shock and adult respiratory distress syndrome), meningitis, pneumonia; and severe burns; and for the treatment of cachexia or wasting syndrome associated with morbid TNF release, consequent to infection, cancer, or organ dysfunction, especially AIDS -related cachexia, e.g., associated with or consequential to HIV infection.

Agents of the Invention are particularly useful for treating diseases of bone metabolism including osteoarthritis, osteoporosis and other inflammatory arthritides.

For the above indications the appropriate dosage will, of course, vary depending, for example, on the particular Agent of the Invention employed, the subject to be treated, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results in animals are obtained at daily dosages of from about 1 to about 10mg/kg/day p.o.. In larger mammals, for example humans, an indicated daily dosage is in the range of from about 50 to about 750mg of Agent of the Invention administered orally once or, more suitably, in divided dosages two to four times/day.

The Agents of the Invention may be administered by any conventional route, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectable solutions or suspensions. Normally for systemic administration oral dosage forms are preferred, although for some indications the Agents of the Invention may also be administered topically or dermally, e.g. in the form of a dermal cream or gel or like preparation or, for the purposes of

application to the eye, in the form of an ocular cream, gel or eye-drop preparation; or may be administered by inhalation, e.g., for treating asthma. Suitable unit dosage forms for oral administration comprise e.g. from 25 to 250mg Novel Compound per unit dosage.


In accordance with the foregoing the present invention also provides in a further series of embodiments:

- A. A method of inhibiting production of soluble TNF, especially TNF α , or of reducing inflammation in a subject (i.e., a mammal, especially a human) in need of such treatment which method comprises administering to said subject an effective amount of an Agent of the Invention, or a method of treating any of the above mentioned conditions, particularly a method of treating an inflammatory or autoimmune disease or condition, e.g. rheumatoid arthritis, or alleviating one or more symptoms of any of the above mentioned conditions.
- B. An Agent of the Invention for use as a pharmaceutical, e.g. for use as an immunosuppressant or antiinflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.
- C. A pharmaceutical composition comprising an Agent of the Invention in association with a pharmaceutically acceptable diluent or carrier, e.g., for use as an immunosuppressant or anti-inflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.
- D. Use of an Agent of the Invention in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent or for use in the prevention, amelioration or treatment of any disease or condition as described above, e.g., an autoimmune or inflammatory disease or condition.

CLAIMS

1. A 2-substituted 4,5-diaryl imidazole in which:
 - i) the nitrogen atom at the 1 position is substituted by a trialkylsilyl-containing substituent, or
 - ii) the substituent at the 2 position is arylalkyl, arylsulfonyl, arylthio arylseleno, aryltelluro, cycloalkyl, cycloalkenyl, alkylcycloalkyl, alkylcycloalkenyl, amino or hydrazino, or mono- or bicyclic N-heterocyclyl in which the N containing ring has six ring members, provided that the substituent at the 2 position is not piperidin-4-yl, 1-carboxylic-acid-tert-butyl-ester-4-benzyl-piperidin-4-yl, 1,4-dimethyl-piperidin-4-yl, 4-benzyl-piperidin-4-yl, or piperidin-4-yl which is further substituted only at the N atom, in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.

2. A compound of formula I



wherein

R₁ is 4-pyridyl, pyrimidinyl, quinazolin-4-yl, quinolyl, isoquinolyl, 1-imidazolyl or 1-benzamidazolyl, which is optionally substituted with one or two substituents each of which is independently selected from

C₁₋₄alkyl, halogen, C₁₋₄alkoxy, C₁₋₄alkylthio, NR₅R₆, or an N-heterocyclyl ring having 5 to 7 ring atoms and optionally containing an additional heteroatom selected from O, S, or N

wherein R₅ and R₆ is each independently C₁₋₄alkyl;

R₂ is phenyl, naphth-1-yl or naphth-2-yl which is optionally substituted by up to 5 substituents;

R_3 is hydrogen,
 heterocyclyl,
 heterocyclylC₁₋₁₀alkyl,
 triC₁₋₄alkylsilylC₁₋₁₀alkoxyC₁₋₄alkyl,
 optionally halo substituted C₁₋₁₀alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₇
 cycloalkyl, C₃₋₇ cycloalkylC₁₋₁₀alkyl, C₅₋₇ cycloalkenyl, aryl, arylC₁₋₁₀
 alkyl, heteroaryl, or heteroarylC₁₋₁₀alkyl,
 optionally mono-or di-C₁₋₄alkyl-substitutedC₀₋₁₀alkyl-oxycarbonyl or -
 oxythiocarbonyl optionally substituted by C₁₋₁₀alkyl, C₃₋₇ cycloalkyl,
 heterocyclyl, heterocyclylC₁₋₁₀alkyl, aryl, arylC₁₋₁₀alkyl, heteroaryl,
 heteroarylC₁₋₁₀alkyl, or
 optionally mono-or di-C₁₋₄alkyl-substitutedC₁₋₁₀alkyl
 -cyano,
 -nitro,
 -hydroxy, -C₁₋₁₀alkoxy, -C₃₋₇cycloalkoxy, -heterocycloxy, -
 heterocyclylC₁₋₁₀alkoxy, -aryloxy, -arylC₁₋₁₀alkoxy, -
 heteroaryloxy, -heteroarylC₁₋₁₀alkoxy (and thio oxy analogues
 thereof),
 optionally substituted amino, carboxylate, thiocarboxylate,
 carbonyl or thiocarbonyl, sulphinyl or sulphonyl;

R_4 is C₀₋₄alkyl mono-or di-C₃₋₇cycloalkyl optionally substituted by -halo, -
 OH, -C₁₋₄ alkyl, -C₁₋₄ alkoxy, -C₁₋₄ thioalkoxy, -nitro, -amino, -C₁₋₄
 alkylsulphinyl, -C₁₋₄ alkylsulphonyl, -carboxylate or -ester,
 -NH₂, NR₇R₈, NHNHR₉,
 wherein independently each R₇, R₈ or R₉ is C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₆
 alkynyl,
 -X- C₅₋₁₀ aryl (including heteroaryl)
 wherein X is S, SO₂, Se, Te or C₁₋₄alkyl,
 mono-or bicyclic N-heterocyclyl in which the N containing ring has six ring
 members,
 or aryl or heteroaryl optionally substituted by up to 4 substituents,
 provided that

when R_3 is not tri C_{1-4} alkylsilyl C_{1-10} alkoxy C_{1-4} alkyl,


R_4 is not aryl or heteroaryl optionally substituted by up to 4 substituents, except when R_4 is mono-or bicyclic N-heterocyclyl in which the N containing ring has six ring members, and

provided that

R_4 is not piperidin-4-yl, 1-carboxylic-acid-tert-butyl-ester-4-benzyl-piperidin-4-yl, 1,4-dimethyl-piperidin-4-yl, 4-benzyl-piperidin-4-yl, or piperidin-4-yl which is further substituted only at the N atom,

in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.


3. A compound according to claim 2 of formula I'



wherein

R_3' is tri C_{1-4} alkylsilyl C_{1-10} alkoxy C_{1-4} alkyl, and R_1 , R_2 and R_4 are as defined in claim 2, in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.

4. A compound according to claim 2 of formula III




III

wherein R_1 , R_2 , R_3 and X are as defined in claim 2 and R_{11} represents from 1 to 5 substituents independently selected from H, halo, OH, C_{1-4} alkyl, C_{1-4}

alkoxy, C₁₋₄ thioalkoxy, nitro, amino, C₁₋₄ alkylsulphinyl, C₁₋₄ alkylsulphonyl, carboxylate or ester, in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.

5. A compound according to claim 2 of formula IV



wherein R₁, R₂ and R₃ are as defined in claim 2, D is C₃₋₇cycloalkyl, C₃₋₇cycloalkenyl or a mono- or bicyclic N-heterocyclyl in which the N containing ring has 6 ring members and X' is a direct bond or -CR₁₂R₁₃-

wherein R₁₂ is H or C₁₋₄alkyl and R₁₃ is H or C₁₋₄alkyl optionally substituted by C₃₋₇cycloalkyl or C₃₋₇cycloalkenyl

in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.

6. 4-(4-fluorophenyl)-5-(4-pyridyl)-1-(2-trimethylsilylethoxymethyl)imidazole;
 4-(4-pyridyl)-5-(4-fluorophenyl)-1-(2-trimethylsilylethoxymethyl)imidazole;
 4-(4-fluorophenyl)-2-((RS)-1-hydroxy-4'-fluorobenzyl)-5-(4-pyridyl)imidazole;
 4-(4-fluorophenyl)-2-(phenylsulfonyl)-5-(4-pyridyl)imidazole;
 4-(4-fluorophenyl)-2-(phenylthio)-5-(4-pyridyl)imidazole;
 4-(4-fluorophenyl)-2-(phenylseleno)-5-(4-pyridyl)imidazole;
 4-(4-fluorophenyl)-2-((1-hydroxy)cyclohexyl)-5-(4-pyridyl)imidazole;
 2-(1-Cyclohexenyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole;
 2-(1,2-Dicyclopropylethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole;
 2-(Cyclopropylmethyl)-4-(4-fluorophenyl)-5-(4-pyridyl)imidazole;
 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,3,5,6-tetrafluoropyridinyl)imidazole;
 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(tropan-3 α -ol-3 β -yl)imidazole;
 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(4-hydroxy-1-methylpiperidin-4-yl)imidazole;

+/- 4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(8-methyl-8-azabicyclo[3.2.1]oct-2-en-3-yl)imidazole

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2-amino-3,5,6-trifluoropyridinyl)imidazole;

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(2,6-diamino-3,5-difluoropyridinyl)imidazole;


4-(4-fluorophenyl)-2-((1-amino)cyclohexyl)-5-(4-pyridyl)imidazole;

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(4-n-butyloxy-1-methylpiperidin-4-yl)imidazole, or

4-(4-Fluorophenyl)-5-(4-pyridyl) 2-(1-methyl-4-piperidenyl)imidazole,

in free or pharmaceutically-acceptable acid addition salt or physiologically-cleavable ester form.

7. A process for the preparation of a compound of formulae III as defined in claim 5 or of a compound of formula IV as defined in claim 6 comprising reacting a compound of formula VIII



wherein R₁ and R₂ are as defined above,

with the corresponding aldehyde, ketone, disulfonylamine, disulfide, diselenide, ditelluride or halide and, if required introducing the desired R₃ substituent or further transforming the product obtained and optionally recovering the compound in free or salt form.

8. A method of inhibiting production of soluble TNF or of reducing inflammation in a subject in need of such treatment which method comprises administering to said subject an effective amount of a compound as defined in claim 1 or 2.

9. A compound as defined in claim 1 or 2 for use as a pharmaceutical, e.g. for use as an immunosuppressant or antiinflammatory agent.
10. A pharmaceutical composition comprising a compound as defined in claim 1 or 2 in association with a pharmaceutically acceptable diluent or carrier, e.g., for use as an immunosuppressant or anti-inflammatory agent.
11. Use of a compound as defined in claim 1 or 2 in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03930

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/04 C07F7/08 A61K31/44 A61K31/695 C07D401/14
C07D451/02 C07D403/04 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07F A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| Y | WO 97 12876 A (MERCK & CO INC) 10 April 1997 cited in the application see claims --- | 1-5,8-11 |
| Y | WO 95 03297 A (SMITHKLINE BEECHAM CORPORATION) 2 February 1995 cited in the application see claims --- | 1-5,8-11 |
| Y | WO 93 14081 A (SMITHKLINE BEECHAM CORPORATION) 22 July 1993 see claims --- | 1-5,8-11 |
| Y | WO 93 14082 A (SMITHKLINE BEECHAM CORP) 22 July 1993 see page 3, line 35 - page 4, line 10; claims --- | 1-5,8-11 |
| -/-- | | |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 October 1998

Date of mailing of the international search report

28/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/03930

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ¹ | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------------------|---|-----------------------|
| A | <p>WO 96 03387 A (G.D.SEARLE & CO)</p> <p>8 February 1996</p> <p>see claims</p> <p>-----</p> | 1-5,8-11 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/03930

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 8
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/03930

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|--|--|
| WO 9712876 A | 10-04-1997 | AU 7514396 A CZ 9801043 A EP 0854870 A NO 981528 A PL 326025 A | 28-04-1997 15-07-1998 29-07-1998 05-06-1998 17-08-1998 |
| WO 9503297 A | 02-02-1995 | AU 7629594 A ZA 9405363 A | 20-02-1995 14-03-1995 |
| WO 9314081 A | 22-07-1993 | AU 3592393 A BG 98902 A BR 9305809 A CA 2127876 A CN 1083473 A CZ 9401688 A EP 0623126 A ES 2053401 A FI 943319 A HU 69714 A JP 7503017 T MX 9300141 A NO 942618 A NZ 249301 A OA 9963 A SK 83594 A US 5686455 A ZA 9300213 A | 03-08-1993 30-06-1995 18-02-1997 22-07-1993 09-03-1994 18-01-1995 09-11-1994 16-07-1994 12-09-1994 28-09-1995 30-03-1995 29-07-1994 30-08-1994 25-06-1996 11-12-1995 08-03-1995 11-11-1997 18-11-1993 |
| WO 9314082 A | 22-07-1993 | AU 3592493 A EP 0624159 A JP 7503018 T | 03-08-1993 17-11-1994 30-03-1995 |
| WO 9603387 A | 08-02-1996 | US 5620999 A AU 3271695 A CA 2195846 A EP 0772601 A | 15-04-1997 22-02-1996 08-02-1996 14-05-1997 |